drugset / Trial / NCT05732662
SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC
NaSingle-groupOpen-labelTreatment
Summary
The entire treatment process is divided into two phases: Phase I SBRT combined with PD-1/CTLA-4 bispecific antibody (AK104) and Phase II AK104 single-agent maintenance therapy.
Timeline
- Start
- 2023-04
- Primary completion
- 2025-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | 10 mg/kg | — |